Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.

Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008 Aug 19; 52(8):626-32.

View in: PubMed

subject areas

Aged
Apolipoproteins B
Cholesterol, HDL
Cholesterol, LDL
Coronary Disease
Diabetic Angiopathies
Female
Fluorobenzenes
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Linear Models
Male
Middle Aged
Pyrimidines
Pyrroles
Rosuvastatin Calcium
Simvastatin
Sulfonamides

authors with profiles

CHRISTIE BALLANTYNE